# A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct07462143/  
OnCo record `nct07462143` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of RC148, CAPOX in colorectal cancer, run by RemeGen Co., Ltd., now recruiting.

## Summary

A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer is a phase 2/3 interventional study registered as NCT07462143 by RemeGen Co., Ltd., with 80 participants planned, started 2026-05-12 and due to reach its primary completion in 2027-05-12. Interventions recorded: RC148 (Dose 1) plus Capecitabine and Oxaliplatin, RC148 (Dose 2) plus Capecitabine and Oxaliplatin. Conditions listed: Colorectal (Colon or Rectal) Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07462143
- Phase: 2/3
- Setting: A Randomized, Multicenter, Phase Ⅱ/Ⅲ Study of RC148 Combined With Chemotherapy Versus Bevacizumab Combined With Chemotherapy as First-line Treatment for Unresectable or Metastatic Colorectal Cancer
- Sponsor: RemeGen Co., Ltd.
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT07462143: https://clinicaltrials.gov/study/NCT07462143

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [RC148](https://onco.cc/drugs/rc148/)
- companies: [RemeGen](https://onco.cc/companies/remegen/)

---
JSON: https://onco.cc/api/v1/entities/nct07462143.json